Glizid XR 30 Tablet contains Gliclazide 30mg, an oral hypoglycemic agent belonging to the sulfonylurea class, indicated for the management of type 2 diabetes mellitus. It functions by stimulating pancreatic beta cells to release insulin, thereby improving glycemic control in patients with non-insulin-dependent diabetes. Glizid XR 30 is formulated as an extended-release tablet, allowing for once-daily dosing which enhances patient compliance and provides a more stable plasma concentration, minimizing fluctuations in blood glucose levels. This medication is typically prescribed as part of a comprehensive diabetes management plan, including diet and exercise, especially when diet alone is insufficient to achieve adequate glycemic control. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and hypersensitivity to sulfonylureas. Common adverse effects include hypoglycemia, gastrointestinal disturbances, and allergic skin reactions. Regular monitoring of blood glucose levels and periodic assessment of renal and hepatic function are recommended during therapy. Dose adjustments may be necessary based on clinical response and tolerability. Glizid XR 30 should be used cautiously in elderly patients and those with cardiovascular disease. Patient education on recognizing and managing hypoglycemia is essential to ensure safe and effective use of this medication.